These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

240 related items for PubMed ID: 12386269

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 5. [Effects of intravenous and oral OCT on secondary hyperparathyroidism in dogs with chronic renal failure].
    Takahashi F, Yorozu K, Kawata Y, Kitamura H, Chiba N, Kubodera N, Slatopolsky E.
    Clin Calcium; 2002 Jun; 12(6):741-8. PubMed ID: 15775360
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of 1,25-dihydroxy-22-oxavitamin D(3) on parathyroid gland function in haemodialysis patients with secondary hyperparathyroidism.
    Kinugasa E, Akizawa T, Takahashi J, Nabeshima K, Ogata H, Nakayama F, Ideura T.
    Nephrol Dial Transplant; 2002 Jun; 17 Suppl 10():20-7. PubMed ID: 12386265
    [Abstract] [Full Text] [Related]

  • 8. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ.
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of the efficacy of an oral calcitriol pulse or intravenous 22-oxacalcitriol therapies in chronic hemodialysis patients.
    Tamura S, Ueki K, Mashimo K, Tsukada Y, Naitoh M, Abe Y, Kawai H, Tsuchida A, Wakamatsu R, Nojima Y.
    Clin Exp Nephrol; 2005 Sep; 9(3):238-43. PubMed ID: 16189633
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses.
    Koshikawa S, Akizawa T, Kurokawa K, Marumo F, Sakai O, Arakawa M, Morii H, Seino Y, Ogata E, Ohashi Y, Akiba T, Tsukamoto Y, Suzuki M.
    Nephron; 2002 Apr; 90(4):413-23. PubMed ID: 11961400
    [Abstract] [Full Text] [Related]

  • 17. No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure.
    Ardissino G, Schmitt CP, Bianchi ML, Daccò V, Claris-Appiani A, Mehls O.
    Kidney Int; 2000 Sep; 58(3):981-8. PubMed ID: 10972662
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.